Articles
Rare disease awareness: Alkaptonuria

Rare disease awareness: Alkaptonuria

Are enough questions being asked of patients who don’t present with typical symptoms of common diseases? Oliver Timmis of the AKU society doesn’t think so and here he explains why doing so could increase rare disease recognition and reduce patient isolation. There are approximately 7000 rare diseases and many patients suffering from them unfortunately face years of misdiagnosis and...

Articles
Rare diseases, orphan drugs and parent companies

Rare diseases, orphan drugs and parent companies

Catherine McLoughlin discusses the investments of pharma and biotech companies in the orphan drug market. If, early on in my career as a lawyer in the life sciences sector, I had a £1.00 for every deal that I did for a biotech company...

Articles
Rare diseases part 1: posing questions that are difficult to answer

Rare diseases part 1: posing questions that are difficult to...

Starting off our rare diseases focus month, Neil Dickinson discusses the impact of orphan drug development, looking at legislation changes and his own personal experiences. The pharmaceutical industry has always been different to most other commercial sectors and almost every point of difference...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. ESMO26: Tango sees 82% ORR with combo in pancreatic cancer
  2. Roche offers $15bn for strategic-level deal with Hansoh
  3. ESMO26: Moderna, MSD reveal cancer jab data early after leak
  4. Clinical trial setup times fall sharply in UK
  5. Despite US policy changes, drug prices stay stubbornly high

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more